Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70115384)
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Accepted: 29 November 2024
First Online: 21 December 2024
Declarations
:
: Open Access funding enabled and organized by Projekt DEA. R.R. reports a grant from German Cancer Aid (Max–Eder Nachwuchsgruppe, Deutsche Krebshilfe, ref. 70115384). R.R. is also funded by the Clinician Scientist Programm of Heidelberg University, Faculty of Medicine and is part of the Cancer Core Europe (CCE) Training program of Young leaders in TRAnslational Cancer research (TRYTRAC).
: Outside of this study, the authors have received the following support: R.R. has received travel expenses from Sunpharma. J.C.H. has received honoraria from Amgen, BMS, Delcath, GSK, MSD, Novartis, Pierre Fabre, Roche, Sanofi, and Sunpharma; has served as a consultant or advisor for GSK, MSD, Pierre Fabre, Sunpharma, Immunocore, Nektar, Novartis, Philogen, Sanofi, BMS, Sunpharma, and Sanofi; and has received research funding or support for clinical studies from BMS, Sunpharma, Sanofi, AstraZeneca, BioNTech, BMS, Genentech/Roche, Genmab, Idera, Immunocore, IOBiotech, Iovance, Nektar, Novartis, Philogen, Pierre Fabre, Regeneron, Replimune, Sanofi, and Seagen. A.E.H. received honoraria by Janssen-Cilag, Biotest, MSD, and Galderma and is president of the European Dermatology Forum (EDF).
: N/A.
: N/A.
: N/A.
: N/A.
: N/A.
: R.R. carried out study conceptualization and wrote the original draft; R.R., J.C.H., and A.E.H. revised the manuscript; J.C.H. carried out study supervision.
